Midodrine and Arrhythmia Risk in Atrial Flutter/Fibrillation

Mechanism and Cardiac Effects

• The American College of Cardiology notes that midodrine's active metabolite, desglymidodrine, acts exclusively on peripheral alpha-1 adrenergic receptors, producing vasoconstriction without direct cardiac stimulation, and does not stimulate cardiac beta-adrenergic receptors, limiting its effects to peripheral vascular tone 1
• Midodrine increases peripheral vascular resistance and blood pressure, which activates arterial baroreceptors, leading to increased vagal tone and reflex bradycardia, a mechanism that is important to understand in patients with atrial flutter or fibrillation 1

Contrast with Pro-Arrhythmic Agents

• The American Heart Association identifies specific classes of drugs that are truly pro-arrhythmic, including class IC drugs (flecainide, propafenone), which can convert AF to atrial flutter with rapid 1:1 AV conduction, potentially causing dangerous ventricular rates 3, 4, 6
• The American College of Cardiology notes that class IA and III drugs are associated with torsades de pointes, QT prolongation, and ventricular proarrhythmia 3, 4, 5

Clinical Monitoring Recommendations

• When using midodrine in patients with atrial flutter or fibrillation, the American College of Cardiology recommends monitoring for supine hypertension, which can be minimized by avoiding doses within several hours of bedtime, and occurs in up to 25% of patients 1

Special Populations

• The American College of Cardiology states that hemodialysis patients with atrial arrhythmias can safely receive midodrine, as it is effectively cleared during dialysis with a reduced half-life of 1.4 hours, though monitoring for reflex bradycardia remains important 1